STANDARD BIOTOOLS INC. (LAB) valuation
Bring your own price
Enter a share price and a discount rate — every multiple, the earning-power value and the reverse-DCF below recompute on the spot from STANDARD BIOTOOLS INC.'s latest SEC EDGAR filings. Change either input and the whole page follows.
The prefilled 8.9% is a plain CAPM cost of equity at β = 1: the 10-year Treasury yield (4.46%, 2026-06-18, U.S. Treasury 10-yr) plus the U.S. equity risk premium (4.46%, Damodaran 2026-01-01). Build a firmer per-company rate with the cost-of-equity and WACC calculators, then paste it here.
Share price — · awaiting your input
Market Capitalization
Enterprise Value
Price-to-Earnings
Earnings Yield
Price-to-Free-Cash-Flow
Free-Cash-Flow Yield
Enterprise-Value-to-EBITDA
Enterprise-Value-to-Sales
Enterprise-Value-to-FCF
Price-to-Sales
Price-to-Book
Underlying EBIT Margin
Fundamentals from the filings
Every model input below comes straight from STANDARD BIOTOOLS INC.'s SEC EDGAR XBRL filings — these are the denominators and bridge inputs the calculator pairs with your price and rate.
Trailing twelve months · TTM as of 2026-03-31 (Q1 FY2026)
- Revenue
- $86.3M
- EBIT (GAAP)
- -$95.8M
- EBIT margin
- -111.0%
- Operating cash flow
- -$90.7M
- CapEx
- $3.8M
- D&A
- $7.4M
- Free cash flow
- -$94.5M
- Stock-based comp
- $29.4M
- YoY revenue growth
- -3.7%
Balance sheet · 10-Q · period ending 2026-03-31
- Cash & investments
- $455.2M
- Total debt
- $29.5M
- Stockholders' equity
- $561.1M
- Excess cash
- $453.5M
Total debt = Long-term debt ($299.0K) + Operating lease liability ($29.2M) — carried forward from the prior annual filing; the latest filing omitted granular debt tagging .
Excess cash = total cash − an operating-cash floor of 2% of TTM revenue ($1.7M) that a buyer couldn't pocket without starving operations.
Share count
- Diluted shares (TSM-scaled)
- 390.1M
Method: point-in-time shares outstanding × 1.0000 (latest filer-disclosed diluted ÷ basic ratio). See the diluted-shares methodology for why this count denominates EPV/share and the reverse-DCF equity bridge.
Earning Power Value & reverse-DCF
A note on share counts — three different denominators in play
- Weighted-average diluted — the filed P/E
denominator (NetIncome ÷ this = diluted EPS). Used on the
P/E card above because EPS is pulled directly from the
EarningsPerShareDilutedXBRL tag and is locked to that share count. - Point-in-time CSO (latest
CommonStockSharesOutstanding) — matches a point-in-time price for market-cap-based multiples (P/S, P/B, EV/EBITDA, P/FCF, FCF Yield). Cards labelled "shares outstanding" use this. - TSM-scaled diluted — point-in-time CSO scaled by the latest filer-disclosed (WeightedAverageDiluted ÷ WeightedAverageBasic) ratio. Estimates today's fully-diluted share count and is the denominator for the EPV per share and the reverse-DCF equity bridge below.
Earning Power Value
Bruce Greenwald's no-growth fair-value floor: capitalise after-tax operating earnings (NOPAT) at your discount rate, then bridge to equity (+ excess cash, − total debt, − minority interest). Assumes today's earnings approximate steady-state earnings power and ignores any growth premium. See the EPV methodology for assumptions and caveats.
- 3-yr avg EBIT margin
- —
- × Revenue (—)
- —
- = Normalized EBIT
- —
- × (1 − tax)
- —
- EBIT (TTM)
- —
- = NOPAT
- —
- − Growth CapEx
- —
- = Earnings power
- —
- ÷ Discount rate
- —
- = Enterprise EPV
- —
- + Excess cash
- $453.5M
- − Total debt
- $29.5M
- − Minority interest
- —
- = Equity EPV
- —
- ÷ Diluted shares
- 390.1M
3-year FY EBIT-margin history isn't available for this filer (typically a recent IPO or restated history) — falling back to TTM-only NOPAT for EPV. The capitalised figure is more sensitive to single-period distortion than the normalized form.
Normalized NOPAT (3-yr-margin × normalisation revenue, after tax) is non-positive — the no-growth EPV floor is undefined because steady-state earnings power requires positive earnings. The reverse-DCF below models a forward-looking path back to profitability.
Expectations investing: what does your price imply?
Rappaport-style reverse-DCF. We start from your share price (— × — shares = — market cap, — enterprise value) and solve for the operating path that would justify it.
To match your price, the model solves for the operating levers below, then flags each against STANDARD BIOTOOLS INC.'s own history:
- Year-1 revenue growth: —
- Target EBIT margin (Y10): —
- High-growth plateau: —
- Starting ROIC held through the harvest window
at or below the reference above the reference outside the historical band
Assumptions
- Initial revenue growth
- —
- Year-2 growth
- —
- Starting EBIT margin
- —
- Tax rate
- —
- Discount rate (your input)
- —
- Starting ROIC
- —
Constants
- Horizon
- 10 years
- Terminal growth
- 2.5%
- Terminal ROIC
- —
- Discounting
- Mid-year
See the discounting convention, plateau tier rules, and the terminal ROIC fade on the methodology page.
Year-by-year reconciliation
Not a forecast. These are the year-by-year revenue, margin, and cash-flow figures the reverse-DCF solver had to assume for its present value to land on the enterprise value your price implies — the operating path that price is pricing in, not a view of what the company will deliver.
| Year | Revenue | Growth | EBIT | Margin | NOPAT | ROIC | Reinvestment | FCF | Discount | PV of FCF |
|---|---|---|---|---|---|---|---|---|---|---|
| Enter a share price above to solve the scenario. | ||||||||||
Terminal value
- NOPATN+1
- —
- ReinvestmentN+1
- —
- FCFN+1
- —
- Terminal value (undiscounted)
- —
- PV of terminal value
- —
Equity bridge
| PV of operating FCF | — |
| + PV of terminal value | — |
| = Enterprise value | — |
| − Total debt | $29.5M |
| + Excess cash | $453.5M |
| − Noncontrolling interest | — |
| = Equity value | — |
| ÷ Diluted shares | 390.1M |
| = DCF PV / share | — |
| Your price | — |
| Reconciliation delta | — |
Every rule — growth-source priority, plateau tiers, compound cap, solver ladder, flag colours — is documented on the expectations scenario methodology.